1782. Regular use of proton pump inhibitors and risk of type 2 diabetes: results from three prospective cohort studies.
作者: Jinqiu Yuan.;Qiangsheng He.;Long H Nguyen.;Martin C S Wong.;Junjie Huang.;Yuanyuan Yu.;Bin Xia.;Yan Tang.;Yulong He.;Changhua Zhang.
来源: Gut. 2021年70卷6期1070-1077页
The association between the regular use of proton pump inhibitors (PPIs) and the risk of type 2 diabetes remains unclear, although a recent randomised controlled trial showed a trend towards increased risk. This study was undertaken to evaluate the regular use of PPIs and risk of type 2 diabetes.
1783. Faecal immunochemical test after negative colonoscopy may reduce the risk of incident colorectal cancer in a population-based screening programme.
作者: Szu-Min Peng.;Wen-Feng Hsu.;Ying-Wei Wang.;Li-Ju Lin.;Amy Ming-Fang Yen.;Li-Sheng Chen.;Yi-Chia Lee.;Ming-Shiang Wu.;Tony Hsiu-Hsi Chen.;Han-Mo Chiu.
来源: Gut. 2021年70卷7期1318-1324页
Subjects with a positive faecal immunochemical test (FIT) have a much higher likelihood of advanced neoplasms than the general population. Whether FIT-positive subjects with negative colonoscopy should receive subsequent FIT screening remain unclear.
1784. Effects of SARS-CoV-2 emergency measures on high-risk lesions detection: a multicentre cross-sectional study.
作者: Manuele Furnari.;Leonardo Henry Eusebi.;Edoardo Savarino.;Carlo Petruzzellis.;Gianluca Esposito.;Marcello Maida.;Luigi Ricciardiello.;Silvia Pecere.;Andrea Buda.;Manuela De Bona.;Cristiano Spada.;Emilio Di Giulio.;Guido Costamagna.;Ivo Boskoski.;Edoardo G Giannini.; .
来源: Gut. 2021年70卷7期1241-1243页 1785. Bacteria-derived long chain fatty acid exhibits anti-inflammatory properties in colitis.
作者: Julien Pujo.;Camille Petitfils.;Pauline Le Faouder.;Venessa Eeckhaut.;Gaelle Payros.;Sarah Maurel.;Teresa Perez-Berezo.;Matthias Van Hul.;Frederick Barreau.;Catherine Blanpied.;Stephane Chavanas.;Filip Van Immerseel.;Justine Bertrand-Michel.;Eric Oswald.;Claude Knauf.;Gilles Dietrich.;Patrice D Cani.;Nicolas Cenac.
来源: Gut. 2021年70卷6期1088-1097页
Data from clinical research suggest that certain probiotic bacterial strains have the potential to modulate colonic inflammation. Nonetheless, these data differ between studies due to the probiotic bacterial strains used and the poor knowledge of their mechanisms of action.
1786. Comparison of the Rome IV criteria with the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care.
作者: Christopher J Black.;Orla Craig.;David J Gracie.;Alexander C Ford.
来源: Gut. 2021年70卷6期1110-1116页
Despite being proposed 4 years ago, there has been no independent validation study of the Rome IV criteria for IBS. We assessed their performance for the diagnosis of IBS in secondary care and compared them with the previous iteration, the Rome III criteria.
1787. Critical thresholds: key to unlocking the door to the prevention and specific treatments for acute pancreatitis.
作者: Savio George Barreto.;Aida Habtezion.;Anna Gukovskaya.;Aurelia Lugea.;Christie Jeon.;Dhiraj Yadav.;Peter Hegyi.;Viktória Venglovecz.;Robert Sutton.;Stephen J Pandol.
来源: Gut. 2021年70卷1期194-203页
Acute pancreatitis (AP), an acute inflammatory disorder of the exocrine pancreas, is one of the most common gastrointestinal diseases encountered in emergency departments with no specific treatments. Laboratory-based research has formed the cornerstone of endeavours to decipher the pathophysiology of AP, because of the limitations of such study in human beings. While this has provided us with substantial understanding, we cannot answer several pressing questions. These are: (a) Why is it that only a minority of individuals with gallstones, or who drink alcohol excessively, or are exposed to other causative factors develop AP? (b) Why do only some develop more severe manifestations of AP with necrosis and/or organ failure? (c) Why have we been unable to find an effective therapeutic for AP? This manuscript provides a state-of-the-art review of our current understanding of the pathophysiology of AP providing insights into the unanswered clinical questions. We describe multiple protective factors operating in most people, and multiple stressors that in a minority induce AP, independently or together, via amplification loops. We present testable hypotheses aimed at halting progression of severity for the development of effective treatments for this common unpredictable disease.
1788. European Registry on Helicobacter pylori management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients.
作者: Olga P Nyssen.;Dmitry Bordin.;Bojan Tepes.;Ángeles Pérez-Aisa.;Dino Vaira.;Maria Caldas.;Luis Bujanda.;Manuel Castro-Fernandez.;Frode Lerang.;Marcis Leja.;Luís Rodrigo.;Theodore Rokkas.;Limas Kupcinskas.;Jorge Pérez-Lasala.;Laimas Jonaitis.;Oleg Shvets.;Antonio Gasbarrini.;Halis Simsek.;Anthony T R Axon.;György Buzás.;Jose Carlos Machado.;Yaron Niv.;Lyudmila Boyanova.;Adrian Goldis.;Vincent Lamy.;Ante Tonkic.;Krzysztof Przytulski.;Christoph Beglinger.;Marino Venerito.;Peter Bytzer.;Lisette Capelle.;Tomica Milosavljević.;Vladimir Milivojevic.;Lea Veijola.;Javier Molina-Infante.;Liudmila Vologzhanina.;Galina Fadeenko.;Ines Ariño.;Giulia Fiorini.;Ana Garre.;Jesús Garrido.;Cristina F Pérez.;Ignasi Puig.;Frederic Heluwaert.;Francis Megraud.;Colm O'Morain.;Javier P Gisbert.; .
来源: Gut. 2021年70卷1期40-54页
The best approach for Helicobacter pylori management remains unclear. An audit process is essential to ensure clinical practice is aligned with best standards of care.
1790. Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals.
作者: Alessandro Mantovani.;Graziana Petracca.;Giorgia Beatrice.;Herbert Tilg.;Christopher D Byrne.;Giovanni Targher.
来源: Gut. 2021年70卷5期962-969页
Follow-up studies have shown that non-alcoholic fatty liver disease (NAFLD) is associated with an increased risk of incident diabetes, but currently, it is uncertain whether this risk changes with increasing severity of NAFLD. We performed a meta-analysis of relevant studies to quantify the magnitude of the association between NAFLD and risk of incident diabetes.
1791. Clinical and genomic characterisation of mismatch repair deficient pancreatic adenocarcinoma.
作者: Robert C Grant.;Robert Denroche.;Gun Ho Jang.;Klaudia M Nowak.;Amy Zhang.;Ayelet Borgida.;Spring Holter.;James T Topham.;Julie Wilson.;Anna Dodd.;Raymond Jang.;Rebecca Prince.;Joanna M Karasinska.;David F Schaeffer.;Yifan Wang.;George Zogopoulos.;Scott Berry.;Diane Simeone.;Daniel J Renouf.;Faiyaz Notta.;Grainne O'Kane.;Jennifer Knox.;Sandra Fischer.;Steven Gallinger.
来源: Gut. 2021年70卷10期1894-1903页
To describe the clinical, pathological and genomic characteristics of pancreatic cancer with DNA mismatch repair deficiency (MMRD) and proficiency (MMRP).
1794. Time series analysis of microbiome and metabolome at multiple body sites in steady long-term isolation confinement.
作者: Qiang Feng.;Xiang Lan.;Xiaoli Ji.;Meihui Li.;Shili Liu.;Jianghui Xiong.;Yanbo Yu.;Zhipeng Liu.;Zi Xu.;Li He.;Ying Chen.;Haisheng Dong.;Pu Chen.;Bin Chen.;Kunlun He.;Yinghui Li.
来源: Gut. 2021年70卷7期1409-1412页 1795. TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms.
作者: Aitor Esparza-Baquer.;Ibone Labiano.;Omar Sharif.;Aloña Agirre-Lizaso.;Fiona Oakley.;Pedro M Rodrigues.;Ekaterina Zhuravleva.;Colm J O'Rourke.;Elizabeth Hijona.;Raul Jimenez-Agüero.;Ioana Riaño.;Ana Landa.;Adelaida La Casta.;Marco Y W Zaki.;Patricia Munoz-Garrido.;Mikel Azkargorta.;Felix Elortza.;Andrea Vogel.;Gernot Schabbauer.;Patricia Aspichueta.;Jesper B Andersen.;Sylvia Knapp.;Derek A Mann.;Luis Bujanda.;Jesus Maria Banales.;Maria Jesus Perugorria.
来源: Gut. 2021年70卷7期1345-1361页
Hepatocellular carcinoma (HCC) is a prevalent and aggressive cancer usually arising on a background of chronic liver injury involving inflammatory and hepatic regenerative processes. The triggering receptor expressed on myeloid cells 2 (TREM-2) is predominantly expressed in hepatic non-parenchymal cells and inhibits Toll-like receptor signalling, protecting the liver from various hepatotoxic injuries, yet its role in liver cancer is poorly defined. Here, we investigated the impact of TREM-2 on liver regeneration and hepatocarcinogenesis.
1796. Inflammatory bowel diseases among first-generation and second-generation immigrants in Denmark: a population-based cohort study.
作者: Manasi Agrawal.;Giulia Corn.;Sarita Shrestha.;Nete Munk Nielsen.;Morten Frisch.;Jean-Frederic Colombel.;Tine Jess.
来源: Gut. 2021年70卷6期1037-1043页
Our objective was to estimate the relative risk of IBD among first-generation and second-generation immigrants in Denmark compared with native Danes.
1797. WASh multicentre randomised controlled trial: water-assisted sigmoidoscopy in English NHS bowel scope screening.
作者: Matthew D Rutter.;Rachel Evans.;Zoe Hoare.;Christian Von Wagner.;Jill Deane.;Shiran Esmaily.;Tony Larkin.;Rhiannon Edwards.;Seow Tien Yeo.;Llinos Haf Spencer.;Emily Holmes.;Brian P Saunders.;Colin J Rees.;Zacharias P Tsiamoulos.;Iosif Beintaris.; .
来源: Gut. 2021年70卷5期845-852页
The English Bowel Cancer Screening Programme invites 55 year olds for a sigmoidoscopy (Bowel Scope Screening (BSS)), aiming to resect premalignant polyps, thus reducing cancer incidence. A national patient survey indicated higher procedural pain than anticipated, potentially impacting on screening compliance and effectiveness. We aimed to assess whether water-assisted sigmoidoscopy (WAS), as opposed to standard CO2 technique, improved procedural pain and detection of adenomatous polyps.
1799. Equivalent performance of single-use and reusable duodenoscopes in a randomised trial.
Single-use duodenoscopes have been recently developed to eliminate risk of infection transmission from contaminated reusable duodenoscopes. We compared performances of single-use and reusable duodenoscopes in patients undergoing endoscopic retrograde cholangiopancreatography (ERCP).
1800. Development and validation of a model to predict survival in colorectal cancer using a gradient-boosted machine.
The success of treatment planning relies critically on our ability to predict the potential benefit of a therapy. In colorectal cancer (CRC), several nomograms are available to predict different outcomes based on the use of tumour specific features. Our objective is to provide an accurate and explainable prediction of the risk to die within 10 years after CRC diagnosis, by incorporating the tumour features and the patient medical and demographic information.
|